Dr Daniel Landau Presents CALQUENCE Long-Term and Pooled Cardiovascular Safety Data for CLL/SLL
22:04
CALQUENCE® (acalabrutinib) ELEVATE-TN, Including 6-Year Median Follow-Up Data – Dr O’ Brien, MD
17:23
CALQUENCE® (acalabrutinib) Pooled Safety Analysis – Dr Pinilla-lbarz, MD
1:08:05
A Patient Story
18:35
CALQUENCE® (acalabrutinib) ACE-CL-001 (ibrutinib-intolerant cohort) – Dr Raval, MD
20:01
CALQUENCE® (acalabrutinib) MAIC of ASCEND and ALPINE – Dr Skarbnik, MD
4:48
CALQUENCE® (acalabrutinib) Patient Testimonials: Emil's Story
15:59
CALQUENCE® (acalabrutinib) Long-Term Data – Dr Brem, MD
14:09